Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (248)	3/22/2002 12:16:23 PM
From: Jibacoa	Read Replies (3) of 544

SUPG The stock tanked on March 5 after ABT terminated their alliance for production and marketing of SUPG's Rubitecan. But SUPG has rebranded Rubitecan, (its oral anticancer compound), as Orathecin and has continued to enroll patients on a Phase III for treatment of pancreatic neoplasms. The insiders and institutions have been buying the stock lately. biz.yahoo.com The short ratio is about 6x the average daily volume. SUPG seems to have found support at the 6 level and it looks like it will close the Mar.5 down-gap.<g> siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next